BR112017009505A2 - composição farmacêutica, e, matriz ou suporte. - Google Patents

composição farmacêutica, e, matriz ou suporte.

Info

Publication number
BR112017009505A2
BR112017009505A2 BR112017009505A BR112017009505A BR112017009505A2 BR 112017009505 A2 BR112017009505 A2 BR 112017009505A2 BR 112017009505 A BR112017009505 A BR 112017009505A BR 112017009505 A BR112017009505 A BR 112017009505A BR 112017009505 A2 BR112017009505 A2 BR 112017009505A2
Authority
BR
Brazil
Prior art keywords
bone
present
bmp
relates
pharmaceutical composition
Prior art date
Application number
BR112017009505A
Other languages
English (en)
Portuguese (pt)
Inventor
Rudolph Carsten
Plank Christian
Balmayor Elizabeth
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Publication of BR112017009505A2 publication Critical patent/BR112017009505A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
BR112017009505A 2014-11-10 2015-11-10 composição farmacêutica, e, matriz ou suporte. BR112017009505A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192539 2014-11-10
PCT/EP2015/076238 WO2016075154A1 (en) 2014-11-10 2015-11-10 Induction of osteogenesis by delivering bmp encoding rna

Publications (1)

Publication Number Publication Date
BR112017009505A2 true BR112017009505A2 (pt) 2018-02-06

Family

ID=51870903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009505A BR112017009505A2 (pt) 2014-11-10 2015-11-10 composição farmacêutica, e, matriz ou suporte.

Country Status (10)

Country Link
US (1) US20180214572A1 (ru)
EP (2) EP3542825A1 (ru)
JP (2) JP2017534649A (ru)
KR (1) KR102647743B1 (ru)
CN (2) CN113786498A (ru)
AU (1) AU2015345164B2 (ru)
BR (1) BR112017009505A2 (ru)
CA (1) CA2966836A1 (ru)
RU (1) RU2718590C2 (ru)
WO (1) WO2016075154A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335498B2 (en) 2014-12-29 2019-07-02 University Of Iowa Research Foundation RNA based biomaterial for tissue engineering applications
US20190275071A1 (en) * 2016-11-23 2019-09-12 Mayo Foundation For Medical Education And Research Particle-mediated delivery of biologics
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
KR102039188B1 (ko) 2018-04-09 2019-10-31 서울대학교산학협력단 다층 그래핀 필름을 포함하는 줄기세포 분화 촉진용 배양 지지체
JP2022522412A (ja) 2019-02-14 2022-04-19 エスリス ゲーエムベーハー 繊毛病の治療
US20210052776A1 (en) * 2019-07-02 2021-02-25 Nevin Witman Mesenchymal stem cells or stromal cells harboring modified rnas encoding vegf and bmp polypeptides
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN111161269B (zh) * 2019-12-23 2024-03-22 上海联影智能医疗科技有限公司 图像分割方法、计算机设备和可读存储介质
CN111012946B (zh) * 2019-12-31 2022-05-17 广州润虹医药科技股份有限公司 一种温敏性磷酸钙骨水泥及其制备方法
CA3196195A1 (en) 2020-11-04 2022-05-12 Carsten Rudolph Use of ifn-lambda mrna for treating viral infections
CA3219195A1 (en) * 2021-06-03 2022-12-08 Magle Chemoswed Ab A pharmaceutically acceptable aqueous gel composition for mrna delivery
WO2023060041A1 (en) * 2021-10-05 2023-04-13 Day Alexander mRNA INDUCED EXPRESSION OF BONE MORPHOGENIC PROTEIN AND RECEPTOR AND METHODS RELATED THERETO
CN114133444A (zh) * 2021-11-25 2022-03-04 中国人民解放军总医院第四医学中心 人源bmp2及其类似物的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
JP4504559B2 (ja) 1997-08-13 2010-07-14 ビオンテックス ラボラトリーズ ゲーエムベーハー 新リポポリアミン、その調製および適用
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
CA2377207C (en) 1999-06-25 2013-01-08 Christian Plank Combinations for introducing nucleic acids into cells
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
EP1409647A4 (en) 2001-04-30 2009-09-09 Yissum Res Dev Co COMPOSITE SKELETONS AND METHODS OF USE THEREOF FOR GENERATING COMPLEX TISSUE GRAFT
WO2003029429A2 (en) * 2001-10-03 2003-04-10 Selective Genetics, Inc. Traversal of nucleic acid molecules through a fluid space and expression in repair cells
WO2003083079A2 (en) * 2002-03-28 2003-10-09 Tissuegene, Inc. Bone generation by gene therapy
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
CN101124316A (zh) * 2004-12-17 2008-02-13 日东电工株式会社 用于转染真核细胞的固定的可降解阳离子聚合物
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
CN101037674A (zh) * 2006-03-15 2007-09-19 上海中信国健药业有限公司 一种含有bmp－7基因的重组腺病毒及其用途
CN1951964B (zh) * 2006-11-06 2010-05-12 上海瑞邦生物材料有限公司 长链型重组人骨形态发生蛋白-2及其制备方法和应用
FR2925491B1 (fr) 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
WO2010065660A2 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
CN102695525B (zh) * 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
US9168230B2 (en) * 2011-05-26 2015-10-27 University Of South Carolina Tetrary gene delivery system for gene therapy and methods of its use
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US20170021036A1 (en) 2013-06-22 2017-01-26 Ethris Gmbh Compositions for introducing rna into cells

Also Published As

Publication number Publication date
CN113786498A (zh) 2021-12-14
WO2016075154A1 (en) 2016-05-19
AU2015345164A1 (en) 2017-05-18
RU2017120359A3 (ru) 2019-05-23
JP2017534649A (ja) 2017-11-24
CA2966836A1 (en) 2016-05-19
JP2021185168A (ja) 2021-12-09
CN107405412A (zh) 2017-11-28
KR102647743B1 (ko) 2024-03-14
JP7373528B2 (ja) 2023-11-02
EP3218012A1 (en) 2017-09-20
AU2015345164B2 (en) 2021-05-06
KR20170081684A (ko) 2017-07-12
RU2718590C2 (ru) 2020-04-08
RU2017120359A (ru) 2018-12-14
EP3542825A1 (en) 2019-09-25
US20180214572A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112017009505A2 (pt) composição farmacêutica, e, matriz ou suporte.
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015014969A2 (pt) micromatriz para entrega de agente terapêutico e métodos de uso
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
BR112013017154A2 (pt) uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
BR112013001296A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
AR099900A1 (es) Rellenos para tejidos blandos con polisacáridos con persistencia mejorada, kit, procedimiento, uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]